The Chip Nobody Talked About — Until Jensen Huang Said Four Words
Marvell Technology is no longer flying under the radar, and the case for owning it goes well beyond one speech.
Marvell Technology is no longer flying under the radar, and the case for owning it goes well beyond one speech.
CRM delivered record Q1 FY2027 results powered by Agentforce — but the price action tells a more complicated story that options traders were already pricing in.
The Nuvalent acquisition is the biggest biopharma deal of the week — and it’s rewriting the playbook for lung cancer investing.
The Claude maker confidentially filed its S-1 at a $965B valuation. The real story isn’t Anthropic — it’s what this does to the listed AI complex.
Marvell Technology (MRVL) may be the most important chip company most investors still haven’t fully priced.
Q1 blowout, raised guidance, oral GLP-1 coverage expansion — LLY is redefining what a pharmaceutical platform looks like.
Jensen Huang called MRVL “the next trillion-dollar company” — what that actually means for investors
Newmont just posted $3.1 billion in free cash flow in a single quarter. The market hasn’t fully noticed.
The cybersecurity leader crossed $5 billion in ARR and announced a 4-for-1 stock split. The post-earnings selloff may be the setup.
Before Anthropic trades publicly, there’s already a trillion-dollar infrastructure play sitting in plain sight